Related Experiment Video
Updated: Sep 13, 2026
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Expression of TIM-3 and LAG-3 in extranodal NK/T cell lymphoma, nasal type
Yuhua Feng1, Meizuo Zhong1, Yiping Liu1
1Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
Objective:
To investigate the expression of TIM-3 and LAG-3 in extranodal NK/T cell lymphoma, nasal type (ENKTL), and evaluate the clinical and prognostic significance of TIM-3 and LAG-3 in ENKTL.
Methods:
A total of 61 human paraffin-embedded specimens including 41 ENKTL and 20 rhinitis were involved. We performed immunohistochemistry to detect the expression of TIM-3 and LAG-3. We analyzed correlation between expression of TIM-3 and LAG-3 and clinicopathological features of ENKTL.
Results:
TIM-3 was positively expressed in 95 (39/41) ENKTL compared with 55% (11/20) in rhinitis, LAG-3 was positively expressed in 95 (39/41) ENKTL compared with 45% (9/20) in rhinitis. A positive correlation was found between TIM-3 and LAG-3. TIM-3 and LAG-3 had no significant correlation with ENKTL patients' age, gender, international prognostic index (IPI) score, B symptoms, LDH level, Ann Arbor stage and treatment regimens. High expression of TIM-3, high IPI score, elevated LDH level and late Ann Arbor stage were shown to be correlated with worse progression free survival (PFS). A multivariate COX regression model show that TIM-3 high expression rate was an independent prognostic factor for ENKTL patients' PFS.
Conclusions:
Our findings indicate that TIM-3 might be a promising predictive indicator for the ENKTL patients.
More Related Videos
05:24Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia
Published on: February 21, 2021
11:02Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line
Published on: February 8, 2022
